![]() |
|
|
Vol. 280, Issue 3, 1137-1146, 1997
Department of Pharmacology and Pediatrics, College of Physicians
and Surgeons of Columbia University, New York, New York
We studied the effects of nibentan on transmembrane action potentials
of canine Purkinje fibers (PF), ventricular epicardial and endocardial
tissues and atrial tissue. Nibentan (1 × 10
8 to
5 × 10
6 M) had no effects on maximum diastolic
potential of all tissues and produced a modest concentration- and
use-dependent decrease in Vmax. However, a remarkable
tissue specificity was observed in its effects on action potential
duration (APD). In PF, the concentration-dependent effect was biphasic:
maximum APD prolongation was attained at 10
7 M, and a
decrease in APD was seen at higher concentrations. In contrast, in
ventricular tissue, nibentan prolonged APD monotonically to a steady
state at 10
6 M. In atrial tissue, a monotonic,
concentration-dependent increase in APD was observed through the
highest concentration. The ability of nibentan to prolong PF APD
significantly diminished as the cycle length shortened (from 2000 to
300 ms), whereas in ventricular and atrial tissues, it showed no
reverse use-dependence. In the physiological range of cycle length,
nibentan did not enhance the spatial inhomogeneity of repolarization.
In PF, it prolonged APD, slightly inhibited Vmax of
Ca++-induced action potentials and completely eliminated
the effects of isoproterenol on normal automaticity. We conclude that
1) nibentan is an antiarrhythmic with a profound ability to prolong
repolarization while decreasing heterogeneity of repolarization and 2)
the extent of nibentan's APD prolongation effect is significantly
different in different cardiac tissues.
This article has been cited by other articles:
![]() |
M.R. Rosen Isolated tissue models and proarrhythmia Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K64 - K69. [Abstract] [PDF] |
||||
![]() |
E. A. Sosunov, R. Z. Gainullin, P. Danilo Jr., E. P. Anyukhovsky, M. Kirchengast, and M. R. Rosen Electrophysiological Effects of LU111995 on Canine Hearts: In Vivo and In Vitro Studies J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 146 - 152. [Abstract] [Full Text] |
||||